Guidance: Single Trial May Be Enough for ABOM Drugs
Sponsors of treatments for acute bacterial otitis media (ABOM), an inflammation of the middle ear, may be able to use a single clinical trial to support an application under some circumstances, according to a final FDA guidance.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.